ArticleJournal of neuro-oncology2019
Tumor recurrence patterns after surgical resection of intracranial low-grade gliomas.
Article in Journal of neuro-oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 2 syntheses or guidelines pooled it, 64 citations in OpenAlex.
- Congress of Neurological Surgeons systematic review and evidence-based guidelines for the role of surgery in the management of patients with diffuse low grade glioma: update.Journal of neuro-oncology · 2025Pooled it
- Malignant Progression of Diffuse Low-grade Gliomas: A Systematic Review and Meta-analysis on Incidence and Related Factors.Neurologia medico-chirurgica · 2022Pooled it
- The Extracellular Matrix, the Silent 'Architect' of Glioma.Biomedicines · 2026Review
- A novel inositol phosphate metabolism signature predicts survival prognosis in low grade glioma.Discover oncology · 2025Article
- A deep learning model to predict glioma recurrence using integrated genomic and clinical data.Communications medicine · 2025Article
- Near-Infrared Photoimmunotherapy in Brain Tumors-An Unexplored Frontier.Pharmaceuticals (Basel, Switzerland) · 2025Review
- TRAF7 knockdown induces cellular senescence and synergizes with lomustine to inhibit glioma progression and recurrence.Journal of experimental & clinical cancer research : CR · 2025Article
- Case Report: Metabolic alterations and cholesterol esterification in a low-grade diffuse astrocytoma patient who progressed to glioblastoma at recurrence.Frontiers in oncology · 2025Article
- Prognostic and predictive determinants in high-grade gliomas: integrating tumor-intrinsic biology with patient and system-level factors.Frontiers in neurology · 2025Review
- Functional and oncological outcomes following more than three consecutive surgical resections for multiple relapses of initially grade 2 IDH-mutated gliomas.Acta neurochirurgica · 2024Article
- Whole-Brain Vascular Architecture Mapping Identifies Region-Specific Microvascular Profiles In Vivo.AJNR. American journal of neuroradiology · 2024Article
- Vascular architecture mapping reveals sex-specific changes in cerebral microvasculature with aging.Imaging neuroscience (Cambridge, Mass.) · 2024Article
- Integration of histone modification-based risk signature with drug sensitivity analysis reveals novel therapeutic strategies for lower-grade glioma.Frontiers in pharmacology · 2024Article
- T2-FLAIR imaging-based radiomic features for predicting early postoperative recurrence of grade II gliomas.Future oncology (London, England) · 2024Article
- Review
- Cellular senescence in glioma.Journal of neuro-oncology · 2023Review
- Differential expression of the circadian clock network correlates with tumour progression in gliomas.BMC medical genomics · 2023Article
- Tumor volume and calcifications as indicators for preoperative differentiation of grade II/III diffuse gliomas.Journal of neuro-oncology · 2023Article
- Surgical Neuro-Oncology: Management of Glioma.Neurologic clinics · 2022Review
- Duchenne muscular dystrophy gene expression is an independent prognostic marker for IDH mutant low-grade glioma.Scientific reports · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionTumor recurrence patterns after resection of intracranial low-grade gliomas (LGG) generally remain obscured. The objective of the present retrospective study was their multifaceted analysis, evaluation of associated factors, and assessment of impact on prognosis.
methodsStudy group comprised 81 consecutive adult patients (46 men and 35 women; median age, 37 years) with recurrent diffuse astrocytomas (DA; 51 cases) and oligodendrogliomas (OD; 30 cases). The median length of follow-up after primary surgery was 6.7 years.
resultsEarly (within 2 years after primary surgery) and non-early (> 2 years after primary surgery) recurrence was noted in 23 (28%) and 58 (72%) cases, respectively. Fast (≤ 6 months) and slow ( > 6 months) radiological progression of relapse was noted in 31 (38%) and 48 (59%) cases, respectively. Tumor recurrence was local and non-local in 71 (88%) and 10 (12%) cases, respectively. Recurrence patterns have differed in OD, IDH1-mutant DA, and IDH wild-type DA. Early onset, fast radiological progression, and non-local site of relapse had statistically significant negative impact on overall survival of patients and were often associated with malignant transformation of the tumor (38 cases). However, in subgroup with extent of resection ≥ 90% (56 cases) no differences in recurrence characteristics were found between 3 molecularly defined groups of LGG.
conclusionsRecurrence patterns after resection of LGG show significant variability, differ in distinct molecularly defined types of tumors, and demonstrate definitive impact on prognosis. Aggressive resection at the time of primary surgery may result in more favorable characteristics of recurrence at the time of its development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.